Compilação de dados referentes a síndrome de Grisel:  exposição de evidências / Compilation of data relating to Grisel syndrome: exhibition of evidence

Andrade, Guilherme Morais; Júnior, Wilson Tomaz da Silva; Souza, Ellen Lelis De; Porto, Pedro Gabriel; Araújo, Carolina de Souza; Martins, Carla Schoffen; Santos, Saulo Soares Dos; Peixoto, Caline Cariry Cabral de Melo; Hayakawa, Thamye Mariane; Rosario, Julia Felix Almeida

doi:10.34119/bjhrv5n2-156

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liposomes, with their unique properties, serve as flexible and adaptable nanocarriers for drug delivery [39]. Their amphiphilic nature enables the encapsulation of both hydrophilic and hydrophobic medications, enhancing their versatility, providing excellent biocompatibility and biodegradability, along with the isolation of the drug from the surrounding medium [39,40]. By preventing direct contact with healthy cells, liposomes can reduce the toxicity of chemotherapeutic drugs, while also enhancing the stability and bioavailability of these compounds [39].…”

Section: Liposomesmentioning

confidence: 99%

RNA Combined with Nanoformulation to Advance Therapeutic Technologies

Lima,

dos Santos,

Souza

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Nucleic acid-based therapies have the potential to address numerous diseases that pose significant challenges to more traditional methods. RNA-based therapies have emerged as a promising avenue, utilizing nanoformulation treatments to target a range of pathologies. Nanoformulation offers several advantages compared to other treatment modalities, including targeted delivery, low toxicity, and bioactivity suitable for drug loading. At present, various types of nanoformulations are available, such as liposomes, polymeric nanoparticles (NPs), magnetic NPs, nanoshells, and solid lipid nanoparticles (SLNs). RNA-based therapy utilizes intracellular gene nanoparticles with messenger RNA (mRNA) emerging prominently in cancer therapy and immunotechnology against infectious diseases. The approval of mRNA-based technology opens doors for future technological advancements, particularly self-amplifying replicon RNA (repRNA). RepRNA is a novel platform in gene therapy, comprising viral RNA with a unique molecular property that enables the amplification of all encoded genetic information countless times. As a result, repRNA-based therapies have achieved significant levels of gene expression. In this context, the primary objective of this study is to furnish a comprehensive review of repRNA and its applications in nanoformulation treatments, with a specific focus on encapsulated nanoparticles. The overarching goal is to provide an extensive overview of the use of repRNA in conjunction with nanoformulations across a range of treatments and therapies.

show abstract